Abnormalities in neuroendocrine stress response in psychosis: The role of endocannabinoids

Psychological Medicine

Volumn 46, Issue 1, 2016, Pages 27-45

  Appiah Kusi, E ^a   Leyden, E ^a   Parmar, S ^a   Mondelli, V ^b   McGuire, P ^a   Bhattacharyya, S ^a  

^a MINISTRY OF DEFENCE   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cannabis; endocannabinoid system; hypothalamic pituitary adrenal axis; psychosis; schizophrenia; stress

Indexed keywords

ENDOCANNABINOID;

HUMAN; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MENTAL STRESS; METABOLISM; NEUROSECRETION; PSYCHOSIS; SCHIZOPHRENIA;

ENDOCANNABINOIDS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; NEUROSECRETORY SYSTEMS; PITUITARY-ADRENAL SYSTEM; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; STRESS, PSYCHOLOGICAL;

EID: 84949533052     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291715001786     Document Type: Review

References (149)

1. Abel KM, O'Keane V, Murray RM (1996). Enhancement of the prolactin response to D-fenfluramine in drug-naive schizophrenic patients. British Journal of Psychiatry 168, 57-60.
2. Aiello G, Horowitz M, Hepgul N, Pariante CM, Mondelli V (2012). Stress abnormalities in individuals at risk for psychosis: A review of studies in subjects with familial risk or with "at risk" mental state. Psychoneuroendocrinology 37, 1600-1613.
3. Akdeniz C, Tost H, Streit F, Haddad L, Wüst S, Schäfer A, Schneider M, Rietschel M, Kirsch P, Meyer-Lindenberg A (2014). Neuroimaging evidence for a role of neural social stress processing in ethnic minority associated environmental risk. JAMA Psychiatry 71, 672-680.
4. Andréasson S, Engström A, Allebeck P, Rydberg U (1987). Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 330, 1483-1486.
5. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE (2002). Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 325, 1212-1213.
6. Arseneault L, Cannon M, Witton J, Murray RM (2004). Causal association between cannabis and psychosis: examination of the evidence. British Journal of Psychiatry 184, 110-117.
7. Barkus E, Morrison PD, Vuletic D, Dickson JC, Ell PJ, Pilowsky LS, Brenneisen R, Holt DW, Powell J, Kapur S (2011). Does intravenous 9-tetrahydrocannabinol increase dopamine release? A SPET study. Journal of Psychopharmacology 25, 1462-1468.
8. Beards S, Gayer-Anderson C, Borges S, Dewey ME, Fisher HL, Morgan C (2013). Life events and psychosis: A review and meta-analysis. Schizophrenia Bulletin 39, 740-747.
9. Bebbington P, Wilkins S, Jones P, Foerster A, Murray R, Toone B, Lewis S (1993). Life events and psychosis. Initial results from the Camberwell Collaborative Psychosis Study. British Journal of Psychiatry 162, 72-79.
10. Beckmann H, Lauer M (1997). The human striatum in schizophrenia. II. Increased number of striatal neurons in schizophrenics. Psychiatry Research: Neuroimaging 68, 99-109.
11. Belvederi Murri M, Pariante CM, Dazzan P, Hepgul N, Papadopoulos AS, Zunszain P, Di Forti M, Murray RM, Mondelli V (2012). Hypothalamic-pituitary-adrenal axis and clinical symptoms in first-episode psychosis. Psychoneuroendocrinology 37, 629-644.
12. Bhattacharyya S, Atakan Z, Martin-Santos R, Crippa J, Kambeitz J, Prata D, Williams S, Brammer M, Collier D, McGuire P (2012a). Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of 9-tetrahydrocannabinol on midbrain and striatal function. Molecular Psychiatry 17, 1152.
13. Bhattacharyya S, Crippa JA, Allen P, Martin-Santos R, Borgwardt S, Fusar-Poli P, Rubia K, Kambeitz J, O'Carroll C, Seal ML (2012b). Induction of psychosis by9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Archives of General Psychiatry 69, 27-36.
14. Bhattacharyya S, Iyegbe C, Atakan Z, Martin-Santos R, Crippa JA, Xu X, Williams S, Brammer M, Rubia K, Prata D, Collier DA, McGuire PK (2014). Protein kinase B (AKT1) genotype mediates sensitivity to cannabis-induced impairments in psychomotor control. Psychological Medicine 44, 3315-3328.
15. Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, Nosarti C, MO'Carroll C, Seal M, Allen P (2010). Opposite effects of 9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35, 764-774.
16. Bloomfield MA, Morgan CJ, Egerton A, Kapur S, Curran HV, Howes OD (2014). Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biological Psychiatry 75, 470-478.
17. Bossong MG, van Berckel BN, Boellaard R, Zuurman L, Schuit RC, Windhorst AD, van Gerven JM, Ramsey NF, Lammertsma AA, Kahn RS (2008). 9-Tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 34, 759-766.
18. Bramon E, Murray RM (2001). A plausible model of schizophrenia must incorporate psychological and social, as well as neuro developmental, risk factors. Dialogues in Clinical Neuroscience 3, 243-256.
19. Breivogel CS, Sim-Selley LJ (2009). Basic neuroanatomy and neuropharmacology of cannabinoids. International Review of Psychiatry 21, 113-121.
20. Brent BK, Giuliano AJ (2007). Psychotic-spectrum illness and family-based treatments: A case-based illustration of the underuse of family interventions. Harvard Review of Psychiatry 15, 161-168.
21. Cantor-Graae E, Selten J-P (2005). Schizophrenia and migration: A meta-analysis and review. American Journal of Psychiatry 162, 12-24.
22. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, Taylor A, Arseneault L, Williams B, Braithwaite A (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biological Psychiatry 57, 1117-1127.
23. Chopra GS, Smith JW (1974). Psychotic reactions following cannabis use in East Indians. Archives of General Psychiatry 30, 24-27.
24. Ciliax BJ, Heilman C, Demchyshyn LL, Pristupa ZB, Ince E, Hersch SM, Niznik HB, Levey AI (1995). The dopamine transporter: immunochemical characterization and localization in brain. Journal of Neuroscience 15, 1714-1723.
25. Clark LD, Bauer W, Cobb S (1952). Preliminary observations on mental disturbances occurring in patients under therapy with cortisone and ACTH. New England Journal of Medicine 246, 205-216.
26. Collip D, Nicolson N, Lardinois M, Lataster T, Van Os J, Myin-Germeys I (2011). Daily cortisol, stress reactivity and psychotic experiences in individuals at above average genetic risk for psychosis. Psychological Medicine 41, 2305-2315.
27. Cullen AE, Zunszain PA, Dickson H, Roberts RE, Fisher HL, Pariante CM, Laurens KR (2014). Cortisol awakening response and diurnal cortisol among children at elevated risk for schizophrenia: relationship to psychosocial stress and cognition. Psychoneuroendocrinology 46, 1-13.
28. D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH (2005). 9-Tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biological Psychiatry 57, 594-608.
29. Day FL, Valmaggia LR, Mondelli V, Papadopoulos A, Papadopoulos I, Pariante CM, McGuire P (2014). Blunted cortisol awakening response in people at ultra high risk of developing psychosis. Schizophrenia Research 158, 25-31.
30. De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V (2003). Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids in Health and Disease 2, 5.
31. Dean B, Sundram S, Bradbury R, Scarr E, Copolov D (2001). Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103, 9-15.
32. Di Forti M, Iyegbe C, Sallis H, Kolliakou A, Falcone MA, Paparelli A, Sirianni M, La Cascia C, Stilo SA, Marques TR (2012). Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biological Psychiatry 72, 811-816.
33. Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA, Marconi A, La Cascia C, Marques TR, Pariante C (2014). Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophrenia Bulletin 40, 1509-1517.
34. Di Marzo V, Berrendero F, Bisogno T, Gonzalez S, Cavaliere P, Romero J, Cebeira M, Ramos J, FernándezRuiz J (2000). Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of 9tetrahydrocannabinoltolerant rats. Journal of Neurochemistry 74, 1627-1635.
35. Di S, Malcher-Lopes R, Halmos KC, Tasker JG (2003). Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: A fast feedback mechanism. Journal of Neuroscience 23, 4850-4857.
36. Di S, Malcher-Lopes R, Marcheselli VL, Bazan NG, Tasker JG (2005). Rapid glucocorticoid-mediated endocannabinoid release and opposing regulation of glutamate and aminobutyric acid inputs to hypothalamic magnocellular neurons. Endocrinology 146, 4292-4301.
37. Dlugos A, Childs E, Stuhr KL, Hillard CJ, de Wit H (2012). Acute stress increases circulating anandamide and other N-acylethanolamines in healthy humans. Neuropsychopharmacology 37, 2416-2427.
38. Eggan SM, Hashimoto T, Lewis DA (2008). Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Archives of General Psychiatry 65, 772-784.
39. Eggan SM, Stoyak SR, Verrico CD, Lewis DA (2010). Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: comparison of schizophrenia and major depressive disorder. Neuropsychopharmacology 35, 2060-2071.
40. Ferdinand RF, Sondeijker F, Van Der Ende J, Selten JP, Huizink A, Verhulst FC (2005). Cannabis use predicts future psychotic symptoms, and vice versa. Addiction 100, 612-618.
41. Fergusson DM, Horwood LJ, Ridder EM (2005). Tests of causal linkages between cannabis use and psychotic symptoms. Addiction 100, 354-366.
42. Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ, Allen P, Martin-Santos R, Seal M, Surguladze SA, O'Carrol C, Atakan Z (2009). Distinct effects of 9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Archives of General Psychiatry 66, 95-105.
43. Gage SH, Zammit S, HickmanM(2013). Stronger evidence is needed before accepting that cannabis plays an important role in the aetiology of schizophrenia in the population. F1000 Medicine Reports 5, 2.
44. Ganon-Elazar E, Akirav I (2011). Cannabinoids prevent the development of behavioral and endocrine alterations in a rat model of intense stress. Neuropsychopharmacology 37, 456-466.
45. Garcia-Rizo C, Fernandez-Egea E, Oliveira C, Justicia A, Parellada E, Bernardo M, Kirkpatrick B (2012). Prolactin concentrations in newly diagnosed, antipsychotic-naïve patients with nonaffective psychosis. Schizophrenia Research 134, 16-19.
46. Garner B, Phassouliotis C, Phillips LJ, Markulev C, Butselaar F, Bendall S, Yun Y, McGorry PD (2011). Cortisol and dehydroepiandrosterone-sulphate levels correlate with symptom severity in first-episode psychosis. Journal of Psychiatric Research 45, 249-255.
47. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG (1996). Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379, 606-612.
48. Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, Klosterkötter J, Piomelli D (2004). Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29, 2108-2114.
49. Gorzalka BB, Hill MN, Hillard CJ (2008). Regulation of endocannabinoid signaling by stress: implications for stress-related affective disorders. Neuroscience and Biobehavioral Reviews 32, 1152-1160.
50. Gracie A, Freeman D, Green S, Garety P, Kuipers E, Hardy A, Ray K, Dunn G, Bebbington P, Fowler D (2007). The association between traumatic experience, paranoia and hallucinations: A test of the predictions of psychological models. Acta Psychiatrica Scandinavica 116, 280-289.
51. Guillin O, Abi-Dargham A, LaruelleM(2007). Neurobiology of dopamine in schizophrenia. International Review of Neurobiology 78, 1-39.
52. Gunduz-Bruce H, Szeszko PR, Gueorguieva R, Ashtari M, Robinson DG, Kane JM, Bilder RM (2007). Cortisol levels in relation to hippocampal sub-regions in subjects with first episode schizophrenia. Schizophrenia Research 94, 281-287.
53. Hauer D, Schelling G, Gola H, Campolongo P, Morath J, Roozendaal B, Hamuni G, Karabatsiakis A, Atsak P, Vogeser M (2013). Plasma concentrations of endocannabinoids and related primary fatty acid amides in patients with post-traumatic stress disorder. PLOS ONE 8, e62741.
54. Heim C, Newport DJ, Heit S, Graham YP,Wilcox M, Bonsall R, Miller AH, Nemeroff CB (2000). Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. JAMA 284, 592-597.
55. Hempel RJ, Tulen JH, Van Beveren NJ, Röder CH, De Jong FH, Hengeveld MW (2010). Diurnal cortisol patterns of young male patients with schizophrenia. Psychiatry and Clinical Neurosciences 64, 548-554.
56. Henquet C, Rosa A, Delespaul P, Papiol S, Faanás L, Van Os J, Myin-Germeys I (2009). COMT Val158Met moderation of cannabis-induced psychosis: A momentary assessment study of 'switching on' hallucinations in the flow of daily life. Acta Psychiatrica Scandinavica 119, 156-160.
57. Henquet C, Rosa A, Krabbendam L, Papiol S, Faanás L, Drukker M, Ramaekers JG, van Os J (2006). An experimental study of catechol-O-methyltransferase Val158Met moderation of 9-tetrahydrocannabinolinduced effects on psychosis and cognition. Neuropsychopharmacology 31, 2748-2757.
58. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991). Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. Journal of Neuroscience 11, 563-583.
59. Hides L, Dawe S, Kavanagh D, Young RM (2006). Psychotic symptom and cannabis relapse in recent-onset psychosis prospective study. British Journal of Psychiatry 189, 137-143.
60. Hill M, Tasker J (2012). Endocannabinoid signaling, glucocorticoid-mediated negative feedback, and regulation of the hypothalamic-pituitary-adrenal axis. Neuroscience 204, 5-16.
61. Hill MN, Carrier EJ, McLaughlin RJ, Morrish AC, Meier SE, Hillard CJ, Gorzalka BB (2008). Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. Journal of Neurochemistry 106, 2322-2336.
62. Hill MN, Kumar SA, Filipski SB, Iverson M, Stuhr KL, Keith JM, Cravatt BF, Hillard CJ, Chattarji S, McEwen BS (2013). Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure. Molecular Psychiatry 18, 1125-1135.
63. Hill MN, McLaughlin RJ, Bingham B, Shrestha L, Lee TT, Gray JM, Hillard CJ, Gorzalka BB, Viau V (2010). Endogenous cannabinoid signaling is essential for stress adaptation. Proceedings of the National Academy of Sciences USA 107, 9406-9411.
64. Hill MN, McLaughlin RJ, Morrish AC, Viau V, Floresco SB, Hillard CJ, Gorzalka BB (2009a). Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology 34, 2733-2745.
65. Hill MN, Miller GE, Carrier EJ, Gorzalka BB, Hillard CJ (2009b). Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology 34, 1257-1262.
66. Hirsch S, Bowen J, Emami J, Cramer P, Jolley A, Haw C, Dickinson M (1996). A one year prospective study of the effect of life events and medication in the aetiology of schizophrenic relapse. British Journal of Psychiatry 168, 49-56.
67. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, Krey JF, Michael Walker J, Holmes PV, Crystal JD, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D (2005). An endocannabinoid mechanism for stress-induced analgesia. Nature 435, 1108-1112.
68. Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, Frank RA (2001). Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Archives of General Psychiatry 58, 322-328.
69. Ivleva EI, Shohamy D, Mihalakos P, Morris DW, Carmody T, Tamminga CA (2012). Memory generalization is selectively altered in the psychosis dimension. Schizophrenia Research 138, 74-80.
70. Jansen LM, Gispen-de Wied CC, Kahn RS (2000). Selective impairments in the stress response in schizophrenic patients. Psychopharmacology 149, 319-325.
71. Jansen LMC, Gispen-de Wied CC, Gademan PJ, De Jonge RCJ, van der Linden JA, Kahn RS (1998). Blunted cortisol response to a psychosocial stressor in schizophrenia. Schizophrenia Research 33, 87-94.
72. Kale A, Naphade N, Sapkale S, Kamaraju M, Pillai A, Joshi S, Mahadik S (2010). Reduced folic acid, vitamin B12 and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: implications for altered one-carbon metabolism. Psychiatry Research 175, 47-53.
73. Kim J, Alger BE (2004). Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus. Nature Neuroscience 7, 697-698.
74. Kim J, Alger BE (2010). Reduction in endocannabinoid tone is a homeostatic mechanism for specific inhibitory synapses. Nature Neuroscience 13, 592-600.
75. Kirschbaum C, Pirke K-M, Hellhammer DH (1993). The 'Trier Social Stress Test'- A tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology 28, 76-81.
76. Kirschbaum C, Wolf O, May M, Wippich W, Hellhammer D (1996). Stress-and treatment-induced elevations of cortisol levels associated with impaired declarative memory in healthy adults. Life Sciences 58, 1475-1483.
77. Koethe D, Giuffrida A, Schreiber D, Hellmich M, Schultze-Lutter F, Ruhrmann S, Klosterkötter J, Piomelli D, Leweke FM (2009). Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. British Journal of Psychiatry 194, 371-372.
78. Kozak KR, Rowlinson SW, Marnett LJ (2000). Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. Journal of Biological Chemistry 275, 33744-33749.
79. Kristensen K, Cadenhead KS (2007). Cannabis abuse and risk for psychosis in a prodromal sample. Psychiatry Research 151, 151-154.
80. Kudielka BM, Kirschbaum C (2005). Sex differences in HPA axis responses to stress: A review. Biological Psychology 69, 113-132.
81. Kuepper R, Ceccarini J, Lataster J, van Os J, van Kroonenburgh M, van Gerven JM, Marcelis M, Van Laere K, Henquet C (2013). 9-Tetrahydrocannabinol-induced dopamine release as a function of psychosis risk: 18F-fallypride positron emission tomography study. PLOS ONE 8, e70378.
82. Lauer M, Beckmann H (1997). The human striatum in schizophrenia. I. Increase in overall relative striatal volume in schizophrenics. Psychiatry Research: Neuroimaging 68, 87-98.
83. Leweke FM, Giuffrida A, Koethe D, Schreiber D, Nolden BM, Kranaster L, Neatby MA, Schneider M, Gerth CW, Hellmich M (2007). Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophrenia Research 94, 29-36.
84. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D (1999). Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10, 1665-1669.
85. López-Moreno JA, González-Cuevas G, Moreno G, Navarro M (2008). The pharmacology of the endocannabinoid system: functional and structural interactions with other neurotransmitter systems and their repercussions in behavioral addiction. Addiction Biology 13, 160-187.
86. Malcher-Lopes R, Di S, Marcheselli VS, Weng F-J, Stuart CT, Bazan NG, Tasker JG (2006). Opposing crosstalk between leptin and glucocorticoids rapidly modulates synaptic excitation via endocannabinoid release. Journal of Neuroscience 26, 6643-6650.
87. Manzanares N, Monseny R, Ortega L, Montalvo I, Franch J, Gutiérrez-Zotes A, Reynolds RM, Walker BR, Vilella E, Labad J (2014). Unhealthy lifestyle in early psychoses: The role of life stress and the hypothalamic-pituitary-adrenal axis. Psychoneuroendocrinology 39, 1-10.
88. Marcelis M, Cavalier E, Gielen J, Delespaul P, Van Os J (2004). Abnormal response to metabolic stress in schizophrenia: marker of vulnerability or acquired sensitization? Psychological Medicine 34, 1103-1111.
89. Marrs WR, Blankman JL, Horne EA, Thomazeau A, Lin YH, Coy J, Bodor AL, Muccioli GG, Hu SS-J, Woodruff G, Fung S, Lafourcade M, Alexander JP, Long JZ, LiW, Xu C, Moller T, Mackie K, Manzoni OJ, Cravatt BF, Stella N (2010). The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nature Neuroscience 13, 951-957.
90. Mátyás F, Urbán GM, Watanabe M, Mackie K, Zimmer A, Freund TF, Katona I (2008). Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. Neuropharmacology 54, 95-107.
91. McEwen BS (2000). The neurobiology of stress: from serendipity to clinical relevance. Brain Research 886, 172-189.
92. McGrath J, Welham J, Scott J, Varghese D, Degenhardt L, Hayatbakhsh MR, Alati R, Williams GM, Bor W, Najman JM (2010). Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Archives of General Psychiatry 67, 440-447.
93. Melis M, Pistis P (2007). Endocannabinoid signaling in midbrain dopamine neurons: more than physiology? Current Neuropharmacology 5, 268-277.
94. Mittal VA, Dhruv S, Tessner KD, Walder DJ, Walker EF (2007). The relations among putative biorisk markers in schizotypal adolescents: minor physical anomalies, movement abnormalities, and salivary cortisol. Biological Psychiatry 61, 1179-1186.
95. Mondelli V, Dazzan P, Hepgul N, Di Forti M, Aas M, D'Albenzio A, Di Nicola M, Fisher H, Handley R, Marques TR (2010). Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: The role of stress and of antipsychotic treatment. Schizophrenia Research 116, 234-242.
96. Monory K, Lutz B (2009). Genetic models of the endocannabinoid system. In Behavioral Neurobiology of the Endocannabinoid System (ed. D. Kendall and S. Alexander), pp. 111-139. Springer: Berlin and Heidelberg.
97. Monteleone P, Filippo CD, Fabrazzo M, Milano W, Martiadis V, Corrivetti G, Monteleone AM, MajM (2014). Flattened cortisol awakening response in chronic patients with schizophrenia onset after cannabis exposure. Psychiatry Research 215, 263-267.
98. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G (2007). Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet 370, 319-328.
99. Moreira FA, Kaiser N, Monory K, Lutz B (2008). Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology 54, 141-150.
100. Müller-Vahl KR, Emrich HM (2008). Cannabis and schizophrenia: Towards a cannabinoid hypothesis of schizophrenia. Expert Review of Neurotherapeutics 8, 1037-1048.
101. Munck A, Guyre P, Holbrook N (1984). Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocrine Reviews 5, 25-44.
102. Murray RM, Mehta M, Di Forti M (2014). Different dopaminergic abnormalities underlie cannabis dependence and cannabis-induced psychosis. Biological Psychiatry 6, 430-431.
103. Murray RM, Morrison PD, Henquet C, Di Forti M (2007). Cannabis, the mind and society: The hash realities. Nature Reviews Neuroscience 8, 885-895.
104. Myin-Germeys I, van Os J (2007). Stress-reactivity in psychosis: evidence for an affective pathway to psychosis. Clinical Psychology Review 27, 409-424.
105. Myin-Germeys I, van Os J, Schwartz JE, Stone AA, Delespaul PA (2001). Emotional reactivity to daily life stress in psychosis. Archives of General Psychiatry 58, 1137-1144.
106. Newell KA, Deng C, Huang X-F (2006). Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Experimental Brain Research 172, 556-560.
107. Pallanti S, Quercioli L, Pazzagli A (1997). Relapse in young paranoid schizophrenic patients: A prospective study of stressful life events, P300 measures, and coping. American Journal of Psychiatry 154, 792-798.
108. Patel S, Roelke CT, Rademacher DJ, Cullinan WE, Hillard CJ (2004). Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 145, 5431-5438.
109. Patel S, Roelke CT, Rademacher DJ, Hillard CJ (2005). Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. European Journal of Neuroscience 21, 1057-1069.
110. Phan KL, Angstadt M, Golden J, Onyewuenyi I, Popovska A, de Wit H (2008). Cannabinoid modulation of amygdala reactivity to social signals of threat in humans. Journal of Neuroscience 28, 2313-2319.
111. Phassouliotis C, Garner BA, Phillips LJ, Bendall S, Yun Y, Markulev C, Kerr M, McGorry PD (2013). Enhanced cortisol suppression following administration of low-dose dexamethasone in first-episode psychosis patients. Australian and New Zealand Journal of Psychiatry 47, 363-370.
112. Pruessner M, Béchard-Evans L, Boekestyn L, Iyer SN, Pruessner JC, Malla AK (2013a). Attenuated cortisol response to acute psychosocial stress in individuals at ultra-high risk for psychosis. Schizophrenia Research 146, 79-86.
113. Pruessner M, Vracotas N, Joober R, Pruessner JC, Malla AK (2013b). Blunted cortisol awakening response in men with first episode psychosis: relationship to parental bonding. Psychoneuroendocrinology 38, 229-240.
114. Rademacher DJ, Meier SE, Shi L, Vanessa Ho W-S, Jarrahian A, Hillard CJ (2008). Effects of acute and repeated restraint stress on endocannabinoid content in the amygdala, ventral striatum, and medial prefrontal cortex in mice. Neuropharmacology 54, 108-116.
115. Reynolds GP, McGowan OO, Dalton CF (2014). Pharmacogenomics in psychiatry: The relevance of receptor and transporter polymorphisms. British Journal of Clinical Pharmacology 77, 654-672.
116. Rössler W, Hengartner MP, Angst J, Ajdacic?Gross V (2012). Linking substance use with symptoms of subclinical psychosis in a community cohort over 30 years. Addiction 107, 1174-1184.
117. Rottanburg D, Ben-Arie O, Robins A, Teggin A, Elk R (1982). Cannabis-associated psychosis with hypomanic features. Lancet 320, 1364-1366.
118. Rubino T, Prini P, Piscitelli F, Zamberletti E, Trusel M, Melis M, Sagheddu C, Ligresti A, Tonini R, Di Marzo V, Parolaro D (2015). Adolescent exposure to THC in female rats disrupts developmental changes in the prefrontal cortex. Neurobiology of Diseases 73, 60-69.
119. Ryan M, Flanagan S, Kinsella U, Keeling F, Thakore JH (2004a). The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sciences 74, 1999-2008.
120. RyanM, Sharifi N, Condren R, Thakore JH (2004b). Evidence of basal pituitary-adrenal overactivity in first episode, drug naive patients with schizophrenia. Psychoneuroendocrinology 29, 1065-1070.
121. Ryan MC, Collins P, Thakore JH (2003). Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. American Journal of Psychiatry 160, 284-289.
122. Sami M, Rabiner EA, Bhattacharyya S (2015). Does cannabis affect dopaminergic signaling in the human brain? A systematic review of evidence to date. European Neuropsychopharmacology 25, 1201-1224.
123. Simpson EH, Kellendonk C, Kandel E (2010). A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron 65, 585-596.
124. Spelman L, Walsh P, Sharifi N, Collins P, Thakore J (2007). Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia. Diabetic Medicine 24, 481-485.
125. Stokes PR, Mehta MA, Curran HV, Breen G, Grasby PM (2009). Can recreational doses of THC produce significant dopamine release in the human striatum? NeuroImage 48, 186-190.
126. Stone JM, Morrison PD, Pilowsky LS (2007). Review: glutamate and dopamine dysregulation in schizophrenia- A synthesis and selective review. Journal of Psychopharmacology 21, 440-452.
127. Strewe C, Feuerecker M, Nichiporuk I, Kaufmann I, Hauer D, Morukov B, Schelling G, Choukèr A (2012). Effects of parabolic flight and spaceflight on the endocannabinoid system in humans. Reviews in the Neurosciences 23, 673-680.
128. Strous RD, Maayan R, Lapidus R, Goredetsky L, Zeldich E, Kotler M, Weizman A (2004). Increased circulatory dehydroepiandrosterone and dehydroepiandrosteronesulphate in first-episode schizophrenia: relationship to gender, aggression and symptomatology. Schizophrenia Research 71, 427-434.
129. Sundquist K, Frank G, Sundquist J (2004). Urbanisation and incidence of psychosis and depression-follow-up study of 4.4 million women and men in Sweden. British Journal of Psychiatry 184, 293-298.
130. Tien AY, Anthony JC (1990). Epidemiological analysis of alcohol and drug use as risk factors for psychotic experiences. Journal of Nervous and Mental Disease 178, 473-480.
131. Tsou K, Nogueron MI, Muthian S, Sañudo-Peña M, Hillard CJ, Deutsch DG, Walker JM (1998). Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry. Neuroscience Letters 254, 137-140.
132. Tzavara ET, Li DL, Moutsimilli L, Bisogno T, Di Marzo V, Phebus LA, Nomikos GG, Giros B (2006). Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: Therapeutic implications. Biological Psychiatry 59, 508-515.
133. Van Os J, Bak M, Hanssen M, Bijl R, De Graaf R, Verdoux H (2002). Cannabis use and psychosis: A longitudinal population-based study. American Journal of Epidemiology 156, 319-327.
134. van Os J, Kapur S (2009). Schizophrenia. Lancet 374, 635-645.
135. van Venrooij JA, Fluitman SB, Lijmer JG, Kavelaars A, Heijnen CJ, Westenberg HG, Kahn RS, Gispen-de Wied CC (2012). Impaired neuroendocrine and immune response to acute stress in medication-naive patients with a first episode of psychosis. Schizophrenia Bulletin 38, 272-279.
136. van Winkel R (2011). Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. Archives of General Psychiatry 68, 148-157.
137. van Winkel R, Stefanis NC, Myin-Germeys I (2008). Psychosocial stress and psychosis. A review of the neurobiological mechanisms and the evidence for gene-stress interaction. Schizophrenia Bulletin 34, 1095-1105.
138. Ventura J, Nuechterlein KH, Lukoff D, Hardesty JP (1989). Aprospective study of stressful life events and schizophrenic relapse. Journal of Abnormal Psychology 98, 407-411.
139. Volk DW, Eggan SM, Horti AG,Wong DF, Lewis DA (2014). Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia. Schizophrenia Research 159, 124-129.
140. Wade MR, Degroot A, Nomikos GG (2006). Cannabinoid CB1 receptor antagonism modulates plasma corticosterone in rodents. European Journal of Pharmacology 551, 162-167.
141. Walker E, Mittal V, Tessner K (2008). Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia. Annual Review of Clinical Psychology 4, 189-216.
142. Walker EF, Diforio D (1997). Schizophrenia: A neural diathesis-stress model. Psychological Review 104, 667-685.
143. Walsh P, Spelman L, Sharifi N, Thakore JH (2005). Male patients with paranoid schizophrenia have greater ACTH and cortisol secretion in response to metoclopramideinduced AVP release. Psychoneuroendocrinology 30, 431-437.
144. Wang H, Lupica CR (2014). Release of endogenous cannabinoids from ventral tegmental area dopamine neurons and the modulation of synaptic processes. Progress in Neuro-Psychopharmacology and Biological Psychiatry 52, 24-27.
145. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G (2002). Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 325, 1199.
146. Zammit S, Owen MJ, Evans J, Heron J, Lewis G (2011). Cannabis, COMT and psychotic experiences. British Journal of Psychiatry 199, 380-385.
147. Zammit S, Spurlock G, Williams H, Norton N, Williams N, O'Donovan MC, Owen MJ (2007). Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. British Journal of Psychiatry 191, 402-407.
148. Zavitsanou K, Garrick T, Huang XF (2004). Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 28, 355-360.
149. Zubin J, Spring B (1977). Vulnerability- A new view of schizophrenia. Journal of Abnormal Psychology 86, 103-126.